Currie Mark G
Known title: DirectorCIK: 0001478244
Associated companies
Transaction History
| IRWD | ▲ Buy | Grant | 63,481 | $0 | 6/16/2026 | View on chart |
| IRWD | ▲ Buy | Grant | 45,000 | $0 | 6/10/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 24,311 | $0 | 6/18/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 22,350 | $0 | 6/20/2023 | View on chart |
| IRWD | ▼ Sell | Open Market | 70,000 | $825K | 8/11/2022 | View on chart |
| IRWD | ▲ Buy | Option Exercise | 190,383 | $2.2M | 6/7/2022 | View on chart |
| IRWD | ▼ Sell | Open Market | 190,383 | $2.3M | 6/7/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 21,571 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Ironwood Pharmaceuticals names Tammi Gaskins as CEO
Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.
Ironwood Pharmaceuticals names Tammi Gaskins as CEO. Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.